Related Experiment Video
Updated: May 31, 2026
07:58
qKAT: Quantitative Semi-automated Typing of Killer-cell Immunoglobulin-like Receptor Genes
Published on: March 6, 2019
Association between kinase insert domain-containing receptor gene polymorphism and haplotypes and ischemic stroke
Seung-Hun Oh1, Kyung-Tae Min, Young-Joo Jeon
1Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
Journal of the Neurological Sciences
|June 28, 2011
Summary
Single nucleotide polymorphisms in the KDR gene, specifically the +1719A>T variant, are linked to an increased risk of ischemic stroke. Haplotypes involving this KDR gene variant also show a significant association with stroke risk in the Korean population.
Area of Science:
- Genetics
- Vascular Biology
- Neurology
Background:
- Kinase insert domain-containing receptor (KDR) is a key regulator of angiogenesis and vascular integrity.
- Understanding genetic predispositions to ischemic stroke is crucial for preventative strategies.
Purpose of the Study:
- To investigate the association between single nucleotide polymorphisms (SNPs) and haplotypes of the KDR gene and the risk of ischemic stroke.
- To explore potential genetic determinants of ischemic stroke in the Korean population.
Main Methods:
- Genotyping of three KDR SNPs (-604T>C, +1192G>A, +1719A>T) in 501 ischemic stroke patients and 478 controls.
- Haplotype analysis of the identified KDR SNPs.
- Subgroup analysis for etiological subtypes of ischemic stroke.
Main Results:
- The KDR +1719A>T polymorphism showed a dose-dependent association with ischemic stroke risk (TT vs. AA: adjusted OR=1.90).
- The +1719T allele was significantly associated with the small vessel disease subtype of ischemic stroke.
- Specific KDR haplotypes (T-G-T, T-A-T, C-G-T) were found to increase the relative risk of ischemic stroke.
Conclusions:
- The KDR +1719A>T polymorphism is a potential genetic determinant for ischemic stroke risk.
- KDR gene haplotypes may also contribute to the genetic susceptibility to ischemic stroke.
More Related Videos
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...